Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.44 |
| ▸ | MGLL | Q99685 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.44 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.42 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.39 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.39 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6940135 | 1.00 | GPR84 (0.46) | GPR84FFAR1PTGS1PTGS2MGLL | |
| SCHEMBL1574549 | 1.00 | GPR84 (0.46) | GPR84FFAR1PTGS1PTGS2MGLL | |
| SCHEMBL6934782 | 1.00 | GPR84 (0.46) | GPR84FFAR1PTGS1PTGS2MGLL | |
| SCHEMBL30634818 | 1.00 | GPR84 (0.46) | GPR84FFAR1PTGS1PTGS2MGLL | |
| Hydrochloric Acid SCHEMBL6934814 | 0.98 | GPR84 (0.44) | GPR84FFAR1PTGS1PTGS2MGLL | |
| SCHEMBL258485 | 0.98 | GPR84 (0.44) | GPR84FFAR1PTGS1PTGS2MGLL | |
| SCHEMBL258604 | 0.98 | GPR84 (0.44) | GPR84FFAR1PTGS1PTGS2MGLL | |
| SCHEMBL6939609 | 0.98 | GPR84 (0.43) | GPR84FFAR1PTGS1PTGS2MGLL | |
| Ethylene Glycol SCHEMBL2111410 | 0.95 | GPR84 (0.42) | GPR84FFAR1PTGS1PTGS2MGLL | |
| 1,4-Butanediol SCHEMBL5574236 | 0.94 | GPR84 (0.41) | GPR84FFAR1PTGS1PTGS2MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 443 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4635501-A2 | SAPONIN DERIVATIVES WITH IMPROVED THERAPEUTIC WINDOW | Sapreme Technologies B.V. (NL) | 2025-10-22 | — | — | EP | claimed |
| US-20250295800-A1 | CONJUGATE OF A SINGLE DOMAIN ANTIBODY, A SAPONIN AND AN EFFECTOR MOLECULE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, THERAPEUTIC USE OF SAID PHARMACEUTICAL COMPOSITION | SAPREME TECH BV (NL) | 2025-09-25 | — | — | US | claimed |
| EP-4003427-B1 | SAPONIN DERIVATIVES WITH IMPROVED THERAPEUTIC WINDOW | SAPREME TECH BV (NL) | 2025-09-17 | — | — | EP | claimed |
| EP-4596052-A2 | THERAPEUTIC COMBINATION OF GALNAC-OLIGONUCLEOTIDE CONJUGATE AND SAPONIN, AND USES THEREOF | Sapreme Technologies B.V. (NL) | 2025-08-06 | — | — | EP | claimed |
| EP-4591938-A2 | CONJUGATE OF SAPONIN, OLIGONUCLEOTIDE AND GALNAC | Sapreme Technologies B.V. (NL) | 2025-07-30 | — | — | EP | claimed |
| EP-4210760-B1 | CONJUGATE OF SAPONIN, OLIGONUCLEOTIDE AND GALNAC | SAPREME TECH BV (NL) | 2025-06-18 | — | — | EP | claimed |
| EP-4171643-B1 | THERAPEUTIC COMBINATION OF GALNAC-OLIGONUCLEOTIDE CONJUGATE AND SAPONIN, AND USES THEREOF | SAPREME TECH BV (NL) | 2025-06-04 | — | — | EP | claimed |
| EP-4529953-A2 | CONJUGATE OF SAPONIN, OLIGONUCLEOTIDE AND GALNAC | Sapreme Technologies B.V. (NL) | 2025-04-02 | — | — | EP | claimed |
| EP-4171641-B1 | CONJUGATE OF GALNAC AND SAPONIN, THERAPEUTIC COMPOSITION COMPRISING SAID CONJUGATE AND A GALNAC-OLIGONUCLEOTIDE CONJUGATE | SAPREME TECH BV (NL) | 2024-10-30 | — | — | EP | claimed |
| EP-4452325-A1 | CONJUGATE OF A SINGLE DOMAIN ANTIBODY, A SAPONIN AND AN EFFECTOR MOLECULE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, THERAPEUTIC USE OF SAID PHARMACEUTICAL COMPOSITION | Sapreme Technologies B.V. (NL) | 2024-10-30 | — | — | EP | claimed |
| EP-2903650-A2 | NONLINEAR SACCHARIDE CONJUGATES | GlaxoSmithKline Biologicals SA (BE) | 2015-08-12 | — | — | EP | claimed |
| US-20140275413-A1 | HEAT AND MOISTURE RESISTANT ANAEROBIC ADHESIVES AND SEALANTS | DESIGNER MOLECULES, INC. (US) | 2014-09-18 | — | — | US | claimed |
| WO-2014053521-A2 | NONLINEAR SACCHARIDE CONJUGATES | NOVARTIS AG (CH) | 2014-04-10 | — | — | WO | claimed |
| EP-2675480-A1 | METHODS OF PREPARATION OF CONJUGATES | ImmunoGen, Inc. (US) | 2013-12-25 | — | — | EP | claimed |
| US-8530573-B2 | Curable monomer vehicle of (meth)acrylates, vinyl ethers/esters, epoxies, urethanes, polyesters, styrenic compounds or allyl compounds and calcium carbonate; nonabrasive adhesive for microelectronic applications; low coefficients of tthermal expansion; thermosetting pastes; rheology; stacked dies | DESIGNER MOLECULES, INC. (US) | 2013-09-10 | — | — | US | claimed |
| WO-2012112687-A1 | METHODS OF PREPARATION OF CONJUGATES | IMMUNOGEN, INC. (US) | 2012-08-23 | — | — | WO | claimed |
| US-20120141416-A1 | MULTIMERIC PEPTIDE CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2012-06-07 | — | — | US | claimed |
| EP-2448965-A1 | MULTIMERIC PEPTIDE CONJUGATES AND USES THEREOF | Angiochem Inc. (CA) | 2012-05-09 | — | — | EP | claimed |
| WO-2011000095-A1 | MULTIMERIC PEPTIDE CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2011-01-06 | — | — | WO | claimed |
| US-20080075963-A1 | Modified calcium carbonate-filled adhesive compositions and methods for use thereof | DESIGNER MOLECULES, INC. | 2008-03-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120141416-A1 | MULTIMERIC PEPTIDE CONJUGATES AND USES THEREOF | LNPEP, DNPEP, VIP | GPR84 910/4885FFAR1 4150/4885PTGS1 3256/4885 |
| US-20250295800-A1 | CONJUGATE OF A SINGLE DOMAIN ANTIBODY, A SAPONIN AND AN EFFECTOR MOLECULE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, THERAPEUTIC USE OF SAID PHARMACEUTICAL COMPOSITION | CYP46A1, HCCS, DHCR7 | GPR84 4189/4885FFAR1 2881/4885PTGS1 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.